HASSAN ALMAAT: Open Payments
NPI 1467418467 · BLOOMFIELD HILLS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,240 in 56 payments from 15 companies in 2025. Trend: 2023 $168 · 2024 $29 · 2025 $1,240
Food & beverage: $1,131Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $320 |
| Otsuka America Pharmaceutical, Inc. | 9 | $162 |
| Lundbeck LLC | 7 | $140 |
| Neurocrine BioSciences, Inc. | 4 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $102 |
| E.R. Squibb & Sons, L.L.C. | 4 | $82 |
| Alkermes, Inc. | 3 | $81 |
| Corium, LLC | 2 | $60 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Janssen Pharmaceuticals, Inc | 2 | $47 |
Products named: REXULTI, AUSTEDO XR, INGREZZA, CAPLYTA, UZEDY, COBENFY, ARISTADA, Azstarys.
Industry payments across MI — which companies pay providers there.
